Otsuki T, Sakaguchi H, Yamada O, Yawata Y, Ueki A
Department of Hygiene, Kawasaki Medical School, Kurashiki, Okayama 701-0192, Japan.
Oncol Rep. 1998 Jul-Aug;5(4):827-32. doi: 10.3892/or.5.4.827.
We investigated the effects of MCNU (methyl-6)3-(2-chloroethyl)-3-nitrosoureido)-6-deoxy- alpha-D-glucopyranoside), a nitrosourea anti-tumor agent developed in Japan, on cell growth and differentiation in five human myeloma cell lines and compared it with relative expression levels of MDR-1 gene. Although 10 microg/ml of MCNU inhibited cell growth in KMM-1 and KMS-5 lines, other three cell lines required 20-40 microg/ml of MCNU to obtain similar growth inhibition. Accumulation up to the G2 phase of the cell cycle was observed in KMM-1 and KMS-5 lines and the cloning efficiency of KMS-5 cells was reduced by MCNU. On the other hand, expression of surface markers on these lines was not altered remarkably except for increased expression of CD38 on KMS-5 cells. However, the effect of MCNU on these cell lines did not correlate to relative expression levels of MDR-1 gene analyzed by RT-PCR. MCNU may inhibit the growth of myeloma cells by the accumulation of these cells up to the G2 phase, but may not affect their differentiation.
我们研究了日本研发的亚硝基脲抗肿瘤药物MCNU（甲基-6）3-（2-氯乙基）-3-亚硝基脲基）-6-脱氧-α-D-吡喃葡萄糖苷）对五种人骨髓瘤细胞系细胞生长和分化的影响，并将其与MDR-1基因的相对表达水平进行了比较。尽管10微克/毫升的MCNU抑制了KMM-1和KMS-5细胞系的细胞生长，但其他三种细胞系需要20-40微克/毫升的MCNU才能获得类似的生长抑制效果。在KMM-1和KMS-5细胞系中观察到细胞周期积累至G2期，且MCNU降低了KMS-5细胞的克隆效率。另一方面，除了KMS-5细胞上CD38表达增加外，这些细胞系表面标志物的表达没有明显改变。然而，MCNU对这些细胞系的作用与通过逆转录聚合酶链反应分析的MDR-1基因的相对表达水平无关。MCNU可能通过使这些细胞积累至G2期来抑制骨髓瘤细胞的生长，但可能不影响其分化。
